← Back to Screener
Spyre Therapeutics, Inc. Common Stock (SYRE)
Price$73.65
Momentum ScoreA
Favorite Metrics
Price vs S&P 500 (26W)137.57%
Price vs S&P 500 (4W)-1.85%
VGM Score94.48
Market Capitalization$6.40B
All Metrics
Book Value / Share (Quarterly)$8.51
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-2.35
Price vs S&P 500 (YTD)116.66%
Net Profit Margin (TTM)-22158.54%
EPS (TTM)$-2.50
10-Day Avg Trading Volume0.92M
EPS Excl Extra (TTM)$-2.50
EPS (Annual)$-2.42
ROI (Annual)-21.70%
Net Profit Margin (5Y Avg)-8769.93%
Cash / Share (Quarterly)$9.40
ROA (Last FY)-19.95%
EBITD / Share (TTM)$-2.94
ROE (5Y Avg)-86.62%
Operating Margin (TTM)-17559.35%
Cash Flow / Share (Annual)$-2.16
P/B Ratio9.53x
P/B Ratio (Quarterly)5.91x
Net Income / Employee (Annual)$-1,521,600
Net Interest Coverage (TTM)-6.19x
ROA (TTM)-27.76%
EPS Incl Extra (Annual)$-2.42
Current Ratio (Annual)13.25x
Quick Ratio (Quarterly)8.71x
3-Month Avg Trading Volume1.01M
52-Week Price Return343.14%
Revenue / Employee (TTM)$0
P/S Ratio (Annual)7218.80x
Asset Turnover (Annual)0.00x
52-Week High$79.54
Operating Margin (5Y Avg)-6607.37%
EPS Excl Extra (Annual)$-2.42
26-Week Price Return145.50%
Quick Ratio (Annual)12.89x
13-Week Price Return81.45%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)8.97x
Enterprise Value$6.30B
Asset Turnover (TTM)0.01x
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-38241.08%
Cash / Share (Annual)$9.68
3-Month Return Std Dev76.05%
Net Income / Employee (TTM)$-1,759,200
ROE (Last FY)-21.70%
Net Interest Coverage (Annual)-2.14x
EPS Basic Excl Extra (Annual)$-2.42
Receivables Turnover (TTM)2.51x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-2.50
Receivables Turnover (Annual)2.51x
ROI (TTM)-31.25%
P/S Ratio (TTM)5199.88x
Pretax Margin (5Y Avg)-8771.48%
Revenue / Share (Annual)$0.00
Price vs S&P 500 (52W)318.78%
Year-to-Date Return124.82%
5-Day Price Return4.41%
EPS Normalized (Annual)$-2.42
ROA (5Y Avg)-66.20%
Net Profit Margin (Annual)-38238.15%
Month-to-Date Return0.20%
EBITD / Share (Annual)$-3.27
Operating Margin (Annual)-27347.97%
ROI (5Y Avg)-86.54%
EPS Basic Excl Extra (TTM)$-2.50
P/B Ratio (Annual)3.55x
Pretax Margin (TTM)-22174.80%
Book Value / Share (Annual)$9.15
Price vs S&P 500 (13W)73.19%
Beta3.01x
Revenue / Share (TTM)$0.00
ROE (TTM)-31.25%
52-Week Low$13.93
mGradeA
vgmGradeA
Show chart for
Earnings Surprise History
Q1 26-0.74est. -0.68
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.48
4.48
4.48
4.48
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
SYRESpyre Therapeutics, Inc. Common Stock | — | — | A | $73.65 |
| LLYEli Lilly & Co. | D | B | B | $1131.42 |
| JNJJohnson & Johnson | D | C | B | $232.77 |
| ABBVABBVIE INC. | D | C | C | $227.23 |
| MRKMerck & Co., Inc. | C | C | B | $120.79 |
| NVSNovartis AG | C | C | C | $149.16 |
| AZNAstraZeneca PLC | D | B | C | $185.95 |
| NVONovo-Nordisk A/S | B | B | B | $42.96 |
| ABTAbbott Laboratories | C | C | D | $91.07 |
| PFEPfizer Inc. | B | C | C | $26.04 |
| BMYBristol-Myers Squibb Co. | B | C | B | $57.27 |
About
Spyre Therapeutics is a clinical-stage biotechnology company developing long-acting antibodies for inflammatory bowel disease and rheumatic diseases. The company's pipeline features extended half-life antibodies targeting α4β7, TL1A, and IL-23, evaluated as monotherapies and pair-wise combinations to improve treatment outcomes and reduce dosing frequency.